DOCSLIB.ORG

Skin Sensitisation Prediction Using in Vitro Screening Methods

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Skin Sensitisation Prediction Using in Vitro Screening Methods Skin sensitisation prediction using in vitro screening methods Chin Lin Wong B. Biotechnology (Hons) A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2015 School of Pharmacy [This page intentionally left blank] Abstract My PhD research project was designed to bring innovation into in vitro methods for identification of industrial chemicals, particularly epoxy resin systems (ERS), with skin sensitising potential as a means to minimise the use of animals for this purpose. In my research, the generalisability of two in vitro methods originally developed and validated for identification of small molecules to assess the skin sensitising potential of ERS was assessed. Specifically, my research focussed on (i) the human cell line activation test (h- CLAT) which mimics the characteristics of Langerhans cells during the maturation process following their activation by chemical sensitisers, and (ii) the direct peptide reactivity assay (DPRA), that assesses the initial interaction between potential chemical sensitisers with human skin proteins. The ERS data generated using these in vitro methods were compared with the skin sensitisation data for the same compounds generated using the widely accepted murine local lymph node assay (LLNA) in order to gain insight into the accuracy and reliability of the in vitro methods. For h-CLAT, I optimised the assay conditions for a 96-well format using 1.6x105 cells/well as well as anti-CD54-FITC and anti-CD86-PE. The relative fluorescent intensity (RFI) of CD54 and CD86 on THP-1 cells was determined using three-coloured flow cytometry. A chemical was regarded as being a positive sensitiser if the RFI of CD54 was >200% and/or that for CD86 was >150%. Five ERS tested in the h-CLAT assay, viz bisphenol A diglycidyl ether (DGEBA), trimethylolpropane triglycidyl ether (TMPTGE), poly(ethyleneglycol) diglycidylether (PEGGE) tetraphenylolethae glycidyl ether (THETGE), and poly[(phenyl glycidyl ether)-co-formaldehyde] (PPGE) gave negative results. These findings imply that the h-CLAT assay undertaken in standard format may be unsuitable for assessing skin sensitisation potential of ERS as the CD54 and CD86 were not induced. To address this issue, I investigated the possibility that ERS induced cytokine release in the h-CLAT assay may be a more sensitive marker of skin sensitisation than changes in expression levels of CD54 and CD86 on THP-1 cells. Encouragingly, concentrations of the cytokines, IL-6 and IL-8, in the cultured THP-1 cell supernatant quantified using a Meso ScaleTM Discovery human pro-inflammatory multiplex immunoassay, were markedly increased in DGEBA, TMPTGE, THETGE and PPGE. For the DPRA, chemicals with known sensitising capacity were incubated with three synthetic heptapeptides, Cor1-C420 (Ac-NKKCDLF), heptapeptides containing cysteine i (Ac-RFAACAA) and lysine (Ac-RFAAKAA) in order to determine the optimal experimental conditions. The sensitising potential of the chemicals were correlated with depletion of each heptapeptide individually in a reaction mixture. The applicability of the DPRA to assess the skin sensitising potential ERS was investigated together with known positive and negative control compounds. The aforementioned heptapeptides were selected as they had been previously shown to have a high correlation with LLNA data when used to assess small molecules. My DPRA findings show that the optimal incubation temperature for incubation of all heptapeptides was 25°C. Importantly, my data also show that the apparent heptapeptides depletion level is affected by the tube materials used for the DPRA. Specifically, Cor1- C420 was stable in polypropylene tubes but failed to meet the assay acceptance criteria for days 1-3 when borosilicate glass tubes were used. As for cysteine, it was not stable on day 3 post-incubation when glass was used for the assay. Although lysine was stable in both polypropylene and glass tubes during the course of the DPRA, the apparent extent of lysine depleted by the chemical, ethyl acrylate, differed between polypropylene (24.7 ± 5.8%) and glass (47.3 ± 7.7%) vials. Another novel finding was instability of the peptide- chemical complex (i.e. Cor1-C420-cinnamaldehyde and cysteine-2,4- dinitrochlorobenzene) suggesting that the complex formation may be partially reversible. This information suggests that data generated by the DPRA in high-throughput format involving the screening of hundreds of chemicals simultaneously, may not be accurate. Poor aqueous solubility of ERS in in vitro assays is a considerable challenge. To address this issue, the solubility of five ERS using a range of solvent:reaction buffer combinations was compared. In brief, a solvent comprising a 1:1 methanol:acetonitrile containing 1% tert-butanol was effective in solubilising these five ERS in reaction buffer. Using this optimised solvent system for dissolution of DGEBA, TMPTGE, THETGE and PPGE, the DPRA data generated were significantly correlated with the LLNA data on skin sensitisation with the exception that PEGGE was positive in the DPRA but classified as a non-sensitiser in the LLNA. In summary, my findings show that there are many challenges to be overcome in future work beyond the scope of my PhD research project in terms of adapting the DPRA and h- CLAT assays to high-throughput format in order to provide accurate information on the skin sensitisation potential of novel industrial chemicals. ii Declaration by author This thesis is composed of my original work, and contains no material previously published or written by another person except where due reference has been made in the text. I have clearly stated the contribution by others to jointly-authored works that I have included in my thesis. I have clearly stated the contribution of others to my thesis as a whole, including statistical assistance, survey design, data analysis, significant technical procedures, professional editorial advice, and any other original research work used or reported in my thesis. The content of my thesis is the result of work I have carried out since the commencement of my research higher degree candidature and does not include a substantial part of work that has been submitted to qualify for the award of any other degree or diploma in any university or other tertiary institution. I have clearly stated which parts of my thesis, if any, have been submitted to qualify for another award. I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, subject to the policy and procedures of The University of Queensland, the thesis be made available for research and study in accordance with the Copyright Act 1968 unless a period of embargo has been approved by the Dean of the Graduate School. I acknowledge that copyright of all material contained in my thesis resides with the copyright holder(s) of that material. Where appropriate I have obtained copyright permission from the copyright holder to reproduce material in this thesis. iii Publications during candidature Peer-reviewed journal articles 1. Wong C.L., Ghassabian S, Smith M.T. and Lam A (2015). In vitro methods for hazard assessment of industrial chemicals – opportunities and challenges. Frontiers in Pharmacology 6:94. doi: 10.3389/fphar.2015.00094. 2. Wong C.L., Lam A, Smith M.T. and Ghassabian S (2015). Optimization of the performance of the direct peptide reactivity assay (DPRA) for assessment of the skin sensitization potential of chemicals. Frontiers in Pharmacology (under review). Conference Abstracts 1. Wong, C.L., Lam, A.L., Wyse, B.D., Smith, M.T. In vitro assessment of chemical sensitisation potential using the human cell line activation test (h-CLAT). In: Abstracts of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) 46th Annual Scientific Meeting; 2012 Dec 2-5, Sydney, Australia. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. (Poster) Awarded a travel grant by ASCEPT to present in the 46th Annual Scientific Meeting Neville-Percy prize finalist 2. Wong, C.L., Lam, A.L., Ghassabian, S., Smith, M.T. Evaluation of in vitro assays as alternative strategies in predicting skin sensitisers. In: Abstracts of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) 47th Annual Scientific Meeting; 2013 Dec 1-4, Melbourne, Australia. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. (Poster) Awarded a travel grant by ASCEPT to present in the 47th Annual Scientific Meeting iv 3. Wong, C.L., Lam, A.L., Ghassabian, S., Smith, M.T. Evaluation of the direct peptide reactivity assay (DPRA) in identifying epoxy resins with skin sensitizing potential. In: Abstract of the Alternatives to Animal Experimentation (ALTEX) 9th World Congress on Alternatives and Animal Use in the Life Sciences (WC9); 2014 Aug 24-28; Prague, Czech Republic. (Poster) Awarded travel grants by Alternatives Congress Trust (ACT) Germany, Stiftung zur Förderung von Ersatz- und Ergänzungsmethoden zur Einschränkung von Tierversuchen (SET) Foundation (Germany) and Info Kinetics Sdn. Bhd. (Malaysia) 4. Wong, C.L., Lam, A.L., Ghassabian, S., Smith, M.T. Evaluation of the direct peptide reactivity assay (DPRA) in identifying epoxy resins with skin sensitizing potential. In: Abstract of the Translation Research Excellence (TRX14); 2014 Oct 24; Brisbane, Australia. (Poster) 5. Wong, C.L., Lam, A.L., Ghassabian, S., Smith, M.T. Evaluation of the direct peptide reactivity assay (DPRA) in identifying epoxy resins with skin sensitizing potential. In: School of Pharmacy Research Higher Degree Day; 2015 Feb 18; Brisbane, Australia. (Poster) v Publications included in this thesis 1. Wong C.L., Ghassabian S, Smith M.T. and Lam A (2015). In vitro methods for hazard assessment of industrial chemicals – opportunities and challenges. Frontiers in Pharmacology 6:94. doi: 10.3389/fphar.2015.00094 - incorporated as Chapter 1 (refer to Appendix for published paper) Contributor Statement of contribution Author Wrote (70%) and edited the paper (60%) Chin Lin Wong (Candidate) Author Edited paper (5%) Sussan Ghassabian Author Edited paper (15%) Maree T.
Load more

Recommended publications
  • University of Groningen Formaldehyde-Releasers In
    University of Groningen Formaldehyde-releasers in cosmetics de Groot, Anton C.; White, Ian R.; Flyvholm, Mari-Ann; Lensen, Gerda; Coenraads, Pieter- Jan Published in: CONTACT DERMATITIS IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2010 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): de Groot, A. C., White, I. R., Flyvholm, M-A., Lensen, G., & Coenraads, P-J. (2010). Formaldehyde- releasers in cosmetics: relationship to formaldehyde contact allergy Part 1. Characterization, frequency and relevance of sensitization, and frequency of use in cosmetics. CONTACT DERMATITIS, 62(1), 18-31. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal.
    [Show full text]
  • Safety Assessment of Imidazolidinyl Urea As Used in Cosmetics
    Safety Assessment of Imidazolidinyl Urea as Used in Cosmetics Status: Re-Review for Panel Review Release Date: May 10, 2019 Panel Meeting Date: June 6-7, 2019 The 2019 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Christina L. Burnett, Senior Scientific Analyst/Writer. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] Distributed for Comment Only -- Do Not Cite or Quote Commitment & Credibility since 1976 Memorandum To: CIR Expert Panel Members and Liaisons From: Christina Burnett, Senior Scientific Writer/Analyst Date: May 10, 2019 Subject: Re-Review of the Safety Assessment of Imidazolidinyl Urea Imidazolidinyl Urea was one of the first ingredients reviewed by the CIR Expert Panel, and the final safety assessment was published in 1980 with the conclusion “safe when incorporated in cosmetic products in amounts similar to those presently marketed” (imurea062019origrep). In 2001, after considering new studies and updated use data, the Panel determined to not re-open the safety assessment (imurea062019RR1sum). The minutes from the Panel deliberations of that re-review are included (imurea062019min_RR1). Minutes from the deliberations of the original review are unavailable.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,854,246 Francois Et Al
    USOO5854246A United States Patent (19) 11 Patent Number: 5,854,246 Francois et al. (45) Date of Patent: Dec. 29, 1998 54 TOPICAL KETOCONAZOLE EMULSIONS 52 U.S. Cl. .......................... 514/252; 514/852; 514/881; 252/106; 252/172; 252/174.11; 252/544; 75 Inventors: Marc Karel Jozef Francois, 252/547; 252/551; 252/555; 252/399 Kalmthout; Eric Carolus Leonarda 58 Field of Search ..................................... 252/106, 173, Snoeckx, Beerse, both of Belgium 252/124.11, 124.23, 544, 547, 551, 555, 399; 514/257, 852, 881 73 Assignee: Janssen Pharmaceutica, N.V., Beerse, Belgium 56) References Cited U.S. PATENT DOCUMENTS 21 Appl. No.: 793,359 4,335,125 6/1982 Heeres et al. ........................... 424/250 22 PCT Filed: Aug. 25, 1995 4.942,162 7/1990 Rosenberg et al. ..................... 514/252 86 PCT No.: PCT/EP95/03366 4,976,953 12/1990 Orr et al. ........ ... 424/47 5,002,974 3/1991 Geria .............. ... 514/782 S371 Date: Feb. 24, 1997 5,215,839 6/1993 Kamishita et al ... 424/45 5,456,851 10/1995 Lin et al. ................................ 252/106 S 102(e) Date: Feb. 24, 1997 Primary Examiner Keith D. MacMillan 87 PCT Pub. No.: WO96/06613 Attorney, Agent, or Firm Mary Appollina 57 ABSTRACT PCT Pub. Date: Mar. 7, 1996 The invention concerns Stable emulsions comprising keto 30 Foreign Application Priority Data conazole having a pH in the range from 6 to 8, characterized Sep. 1, 1994 EP European Pat. Off. ............ 942O2SOS in that the emulsions lack Sodium Sulfite as an antioxidant; process of preparing Said emulsions.
    [Show full text]
  • Formaldehyde and Formaldehyde Releasers
    INVESTIGATION REPORT FORMALDEHYDE AND FORMALDEHYDE RELEASERS SUBSTANCE NAME: Formaldehyde IUPAC NAME: Methanal EC NUMBER: 200-001-8 CAS NUMBER: 50-00-0 SUBSTANCE NAME(S): - IUPAC NAME(S): - EC NUMBER(S): - CAS NUMBER(S):- CONTACT DETAILS OF THE DOSSIER SUBMITTER: EUROPEAN CHEMICALS AGENCY Annankatu 18, P.O. Box 400, 00121 Helsinki, Finland tel: +358-9-686180 www.echa.europa DATE: 15 March 2017 CONTENTS INVESTIGATION REPORT – FORMALDEHYDE AND FORMALDEHYDE RELEASERS ................ 1 1. Summary.............................................................................................................. 1 2. Report .................................................................................................................. 2 2.1. Background ........................................................................................................ 2 3. Approach .............................................................................................................. 4 3.1. Task 1: Co-operation with FR and NL ..................................................................... 4 3.2. Task 2: Formaldehyde releasers ........................................................................... 4 4. Results of investigation ........................................................................................... 6 4.1. Formaldehyde..................................................................................................... 6 4.2. Information on formaldehyde releasing substances and their uses ............................ 6 4.2.1.
    [Show full text]
  • Imidazolidinyl Urea
    Imidazolidinyl urea 39236-46-9 OVERVIEW This material was prepared for the National Cancer Institute (NCI) for consideration by the Chemical Selection Working Group (CSWG) by Technical Resources International, Inc. under contract no. N02-07007. Imidazolidinyl urea came to the attention of the NCI Division of Cancer Biology (DCB) as the result of a class study on formaldehyde releasers. Used in combination with parabens, imidazolidinyl urea is one of the most widely used preservative systems in the world and is commonly found in cosmetics. Based on a lack of information in the available literature on the carcinogenicity and genetic toxicology, DCB forwarded imidazolidinyl urea to the NCI Short-Term Toxicity Program (STTP) for mutagenicity testing. Based on the results from the STTP, further toxicity testing of imidazolidinyl urea may be warranted. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY Dr. John Walker, Executive Director of the TSCA Interagency Testing Committee (ITC), provided information on the production volumes for this chemical. Dr. Harold Seifried of the NCI provided mutagenicity data from the STTP. NOMINATION OF IMIDAZOLIDINYL UREA TO THE NTP Based on a review of available relevant literature and the recommendations of the Chemical Selection Working Group (CSWG) held on December 17, 2003, NCI nominates this chemical for testing by the National Toxicology Program (NTP) and forwards the following information: • The attached Summary of Data for Chemical Selection • Copies of references cited in the Summary of Data for Chemical Selection • CSWG recommendations to: (1) Evaluate the chemical for genetic toxicology in greater depth than the existing data, (2) Evaluate the disposition of the chemical in rodents, specifically for dermal absorption, (3) Expand the review of the information to include an evaluation of possible break- down products, especially diazolidinyl urea and formaldehyde.
    [Show full text]
  • Diazolidinyl Urea
    Diazolidinyl urea sc-234554 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Diazolidinyl urea STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Company: Santa Cruz Biotechnology, Inc. Address: 2145 Delaware Ave Santa Cruz, CA 95060 Telephone: 800.457.3801 or 831.457.3800 Emergency Tel: CHEMWATCH: From within the US and Canada: 877-715-9305 Emergency Tel: From outside the US and Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 PRODUCT USE Preservative; laboratory reagent. SYNONYMS C8-H14-N4-O7, "Germall II", "Germall II", diazolidinylurea, "urea, N-[1, 3-bis(hydroxymethyl)-2, 5-dioxo-4-imidazolidinyl]-", "urea, N-[1, 3-bis(hydroxymethyl)-2, 5-dioxo-4-imidazolidinyl]-", "N, N' -bis(hydroxymethyl)-", "N, N' -bis(hydroxymethyl)-", "N-(1, 3-bis(hydroxymethyl)-2, 5-dioxo-4-midazolidinyl)-", "N-(1, 3-bis(hydroxymethyl)-2, 5-dioxo-4-midazolidinyl)-", "N, N' -bis(hydroxymethyl)urea", "N, N' -bis(hydroxymethyl)urea", "Unidiacide U26", "N-(hydroxymethyl)-N-(1, 3-dihydroxymethyl-2, 5-dioxo-4-imidazolidinyl)-", "N-(hydroxymethyl)-N-(1, 3-dihydroxymethyl-2, 5-dioxo-4-imidazolidinyl)-", "N' -(hydroxymethyl)urea", "N' -(hydroxymethyl)urea", "imidazolidinyl urea 11", "Germaben II", "Germaben II", "Integra 22" Section 2 - HAZARDS IDENTIFICATION CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK 1 of 16 May cause SENSITIZATION by skin contact. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED • Accidental ingestion of the material may be damaging to the health of the individual. EYE • There is some evidence that material may produce eye irritation in some persons and produce eye damage 24 hours or more after instillation.
    [Show full text]
  • Cosmetic Compositions with Tricyclodecane Amides Kosmetische Zusammensetzungen Mit Trizyklodekanamiden Composition Cosmétique Contenant Les Amides De Tricyclododecane
    (19) TZZ Z _T (11) EP 2 969 026 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 8/34 (2006.01) A61K 8/06 (2006.01) 01.11.2017 Bulletin 2017/44 A61K 8/365 (2006.01) A61Q 17/04 (2006.01) C07D 211/16 (2006.01) C07D 307/22 (2006.01) (2006.01) (2006.01) (21) Application number: 14708585.6 C07D 217/06 C07D 215/08 C07C 233/58 (2006.01) C07D 211/66 (2006.01) C07D 211/60 (2006.01) C07D 211/62 (2006.01) (22) Date of filing: 10.03.2014 C07D 205/04 (2006.01) C07D 207/06 (2006.01) A61K 8/04 (2006.01) A61K 8/368 (2006.01) A61K 8/42 (2006.01) A61K 8/37 (2006.01) A61K 8/49 (2006.01) A61K 8/63 (2006.01) A61Q 19/00 (2006.01) (86) International application number: PCT/EP2014/054604 (87) International publication number: WO 2014/139963 (18.09.2014 Gazette 2014/38) (54) COSMETIC COMPOSITIONS WITH TRICYCLODECANE AMIDES KOSMETISCHE ZUSAMMENSETZUNGEN MIT TRIZYKLODEKANAMIDEN COMPOSITION COSMÉTIQUE CONTENANT LES AMIDES DE TRICYCLODODECANE (84) Designated Contracting States: • CLOUDSDALE, Ian Stuart AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Chapel Hill, North Carolina 27516 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • AU, Van PL PT RO RS SE SI SK SM TR Trumbull, Connecticut 06611 (US) • LEE, Jianming (30) Priority: 13.03.2013 US 201361778831 P Trumbull, Connecticut 06611 (US) • DICKSON, JR, John Kenneth (43) Date of publication of application: Apex, North Carolina 27523 (US) 20.01.2016 Bulletin 2016/03 (74) Representative: Corsten, Michael Allan (73) Proprietors: Unilever N.V.
    [Show full text]